Operating Expenses
Acquired In-Process Research and Development Expenses
Gilead Sciences Acquired In-Process Research and Development Expenses decreased by 80.1% to $107.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 57.7%, from $253.00M to $107.00M. Over 4 years (FY 2021 to FY 2025), Acquired In-Process Research and Development Expenses shows relatively stable performance with a 2.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2018
Last reportedQ1 2026May 7, 2026
How to read this metric
High levels indicate an aggressive acquisition strategy to fill pipeline gaps, which may lead to future revenue growth.
Detailed definition
Acquired in-process research and development expenses represent the upfront costs paid to acquire external research proj...
Peer comparison
Common in biopharma; peers often use M&A to supplement internal R&D efforts.
Metric ID:
gild_acquired_iprd_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $234.75M | $234.75M | $234.75M | $8.00M | $330.00M | $448.00M | $158.00M | $481.00M | $236.00M | $91.00M | $347.00M | $4.13B | $38.00M | $505.00M | $0.00 | $253.00M | $61.00M | $170.00M | $539.00M | $107.00M |
| QoQ Change | — | +0.0% | +0.0% | -96.6% | >999% | +35.8% | -64.7% | +204.4% | -50.9% | -61.4% | +281.3% | >999% | -99.1% | >999% | -100.0% | — | -75.9% | +178.7% | +217.1% | -80.1% |
| YoY Change | — | — | — | — | +40.6% | +90.8% | -32.7% | >999% | -28.5% | -79.7% | +119.6% | +758.8% | -83.9% | +454.9% | -100.0% | -93.9% | +60.5% | -66.3% | — | -57.7% |
Range$0.00 – $4.13B
CAGR-15.2%
Avg YoY Growth+459.7%
Median YoY Growth-28.5%
Acquired In-Process Research and Development Expenses at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's acquired in-process research and development expenses?
- Gilead Sciences (GILD) reported acquired in-process research and development expenses of $107.00M in Q1 2026.
- How has Gilead Sciences's acquired in-process research and development expenses changed year-over-year?
- Gilead Sciences's acquired in-process research and development expenses decreased by 57.7% year-over-year, from $253.00M to $107.00M.
- What is the long-term trend for Gilead Sciences's acquired in-process research and development expenses?
- Over 4 years (2021 to 2025), Gilead Sciences's acquired in-process research and development expenses has grown at a 2.2% compound annual growth rate (CAGR), from $939.00M to $1.02B.
- What does acquired in-process research and development expenses mean?
- Costs associated with buying research projects from other companies that are still in the development phase.